[
    "nase inhibitors that are small molecules, (7) MET inhibitors, (8) ABL kinase inhibitors, (9) ALK inhibitors, (10) FLT-kinase inhibitors, (11) MAPK/ERK kinase (MEK) inhibitors, (12) RAF kinase inhibitors, (13) farnesyl transferase inhibitors, (14) estrogen receptor antagonists or selective estrogen receptor modulators (SERMs), (15) anti-tumor nucleoside derivatives, (16) epothilones, (17) topoisomerase inhibitors, (18) vinca alkaloids, (19) antibodies that are inhibitors of integrins, (20) small molecules that are inhibitors of integrins, (21) folate antagonists, (22) ribonucleotide reductase inhibitors, (23) anthracyclines, (24) biologies; (25) thalidomide (or related imid), (26) heat shock protein 90 inhibitors.</p>Antineoplastic agents that can be used in combination with the kinase inhibitors (i.e. the compounds of compound of Formula 1, 2, 3, or 4) are:</p>(1) Taxanes such as paclitaxel (TAXOL) and/or docetaxel (Taxotere); (2) Platinum coordinator compounds, such as, for example, carboplatin, cisp latin and oxaliplatin; \n\n (3) EGF inhibitors that are antibodies, such as: HER2 antibodies (such as, for example trastuzumab (Herceptin), Genentech, Inc.), Cetuximab (Erbitux, IMC-C225, ImClone Systems), EMD 72000 (Merck KGaA), anti-EFGR monoclonal antibody ABX (Abgenix), TheraCIM-h-R3 (Center of Molecular Immunology), monoclonal antibody 425 (Merck KGaA), monoclonal antibody ICR-62 (ICR, Sutton, England); Herzyme (Elan Pharmaceutical Technologies and Ribozyme Pharmaceuticals), PKI 166</p>(Novartis), EKB 569 (Wyeth-Ayerst), GW 572016 (Glaxo SmithKline), Cl 1033 (Pfizer Global Research and Development), trastuzmab-maytansinoid conjugate (Genentech, Inc.), mitumomab (Imclone Systems and Merck KGaA) and Melvax II (Imclone Systems and Merck KgaA); (4) EGF inhibitors that are small molecules, such as, Tykerb (GSK), Tarceva</p>(OSI-774, OSI Pharmaceuticals, Inc.), and Iressa (ZD 1839, Astra Zeneca);</p>(5) VEGF inhibitors that are antibodies such as: bevacizumab (Genentech, Inc.), and IMC-I CI l (ImClone Systems), DC 101 (a KDR VEGF Receptor 2 from ImClone Systems); (6) VEGF kinase inhibitors that are small molecules such as SU 5416 and SU</p>6688 (both from Sugen, Inc.);</p>(7) Estrogen Receptor Antagonists or Selective Estrogen Receptor Modulators (SERMs), such as tamoxifen, idoxifene, raloxifene, trans-2,3-dihydroraloxifene, levormeloxifene, droloxifene, MDL 103,323, and acolbifene (Schering Corp.); (8) ABL kinase inhibitors such as Gleevec (Novartis);</p>(9) FLT-kinase inhibitors, such as CEP-701 (Cephalon);</p>(10) MEK inhibitors such as CI- 1040 (Pfizer), AZD 6244 (Array Biopharma);</p>(11) RAF kinase inhibitors such as Nevaxar/Sorafenib (Bayer/Onyx);</p>(12) Anti-tumor nucleoside derivatives such as 5-fluorouracil, gemcitabine or capecitabine;</p>(13) Epothilones such as BMS-247550 (Bristol-Myers Squibb), and EP0906 (Novartis Pharmaceuticals);</p>(14) Topoisomerase inhibitors such as topotecan (Glaxo SmithKline), and Camptosar (Pharmacia); (15) Vin",
    "ple, Docetaxel (e.g., Taxotere) can be administered once per week in an amount of about 10 to about 45. In another example Docetaxel (e.g.,</p>Taxotere) can be administered once every three weeks in an amount of about 50 to about 100 mg/m<sup>2</sup>.</p>In another example Cisplatin can be administered once per week in an amount of about 20 to about 40 mg/m<sup>2</sup>. In another example Cisplatin can be administered once every three weeks in an amount of about 60 to about 100 mg/m<sup>2</sup>.</p>In another example Carboplatin can be administered once per week in an amount to provide an AUC of about 2 to about 3. In another example Carboplatin can be administered once every three weeks in an amount to provide an AUC of about 5 to about 8. Antineoplastic agents that can be used in combination with the compounds of</p>Formula 1, 2, 3 or 4 are:</p>(1) Taxanes such as paclitaxel (TAXOL) and/or docetaxel (Taxotere);</p>(2) Platinum coordinator compounds, such as, for example, carboplatin, cisplatin and oxalip latin; (3) EGF inhibitors that are antibodies, such as: HER2 antibodies (such as, for example trastuzumab (Herceptin, Genentech, Inc.), Cetuximab (Erbitux, HVIC-C225, ImClone Systems), EMD 72000 (Merck KGaA), anti-EFGR monoclonal antibody ABX \n\n (Abgenix), TheraCIM-h-R<sup>3</sup> (Center of Molecular Immunology), monoclonal antibody 425 (Merck KGaA), monoclonal antibody ICR-62 (ICR, Sutton, England); Herzyme (Elan Pharmaceutical Technologies and Ribozyme Pharmaceuticals), PKI 166 (Novartis), EKB 569 (Wyeth-Ayerst), GW 572016 (Glaxo Smithkline), CI 1033 (Pfizer Global Research and Development), trastuzmab-maytansinoid conjugate (Genentech, Inc.), mitumomab (Imclone Systems and Merck KGaA) and Melvax II (Imclone Systems and Merck KgaA);</p>(4) EGF inhibitors that are small molecules, such as, Tarceva (TM) (OSI-774, OSI Pharmaceuticals, Inc.), and Iressa (ZD 1839, Astra Zeneca);</p>(5) VEGF inhibitors that are antibodies such as: bevacizumab (Genentech, Inc.), and IMC- 1 C 11 (ImClone Systems), DC 101 (a KDR VEGF Receptor 2 from ImClone</p>Systems);</p>(6) VEGF kinase inhibitors that are small molecules such as SU 5416 and SU 6688 (both from Sugen, Inc.);</p>(7) Estrogen receptor antagonists or selective estrogen receptor modulators (SERMs), such as tamoxifen, idoxifene, raloxifene, trans-2,3-dihydro raloxifene, levormeloxifene, droloxifene, MDL 103,323, and acolbifene (Schering Corp.);</p>(8) ABL kinase inhibitors such as Gleevec (Novartis);</p>(9) FLT-kinase inhibitors, such as CEP-701 (Cephalon);</p>(10) MEK inhibitors such as CI- 1040 (Pfizer), AZD 6244 (Array Biopharma); (11) RAF kinase inhibitors such as Nevaxar/Sorafenib (Bayer/Onyx);</p>(12) Anti-tumor nucleoside derivatives such as 5-fluorouracil, gemcitabine or capecitabine;</p>(13) Epothilones such as BMS-247550 (Bristol-Myers Squibb), and EP0906 (Novartis Pharmaceuticals); (14) Topoisomerase inhibitors such as topotecan (Glaxo SmithKline), and</p>Camptosar (Pharmacia);</p>(15) Vinca a"
]